<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943345</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 09-3-034</org_study_id>
    <nct_id>NCT00943345</nct_id>
  </id_info>
  <brief_title>Validation of New Tests for Gastrointestinal (GI) Permeability</brief_title>
  <acronym>Permeability</acronym>
  <official_title>Dubbelblind Crossover Study for Validation of New Tests for Gastrointestinal (GI) Permeability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Top Institute Food and Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: The primary function of the gastrointestinal (GI) wall is digestion and&#xD;
      absorption of nutrients that are important for growth and development. The second important&#xD;
      function of the GI wall is forming an effective barrier to prevent penetration of potentially&#xD;
      harmful components from the inside of the gut (lumen), via the GI wall, into the body.&#xD;
&#xD;
      A compromised barrier function may play an important role in the development of a range of&#xD;
      inflammatory GI diseases such as coeliac disease, Inflammatory Bowel Disease (IBD), food&#xD;
      allergy, but also in the pathophysiology of postoperative complications. It is important and&#xD;
      clinically relevant to have reliable GI permeability tests, however the existing test leave&#xD;
      room for improvement.&#xD;
&#xD;
      Rationale/aim: Three new tests are developed to assess gastrointestinal permeability in both&#xD;
      normal controls with and without raised permeability, and in patients with coeliac disease.&#xD;
      In the current study these new permeability tests will be evaluated and compared with the&#xD;
      golden standard permeability test, the dual sugar test.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of permeability tests (new versus golden standard dual sugar test)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GI permeability</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Gastrointestinal Diseases</condition>
  <arm_group>
    <arm_group_label>GS dual sugar permeability test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Golden standard GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).&#xD;
Coeliac patients will only have 1 test to assess basal GI permeability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi sugar test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).&#xD;
Coeliac patients will only have 1 test to assess basal GI permeability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).&#xD;
Coeliac patients will only have 1 test to assess basal GI permeability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).&#xD;
Coeliac patients will only have 1 test to assess basal GI permeability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indometacin</intervention_name>
    <description>capsule for oral consumption&#xD;
at 22h00 evening before test day: 75 mg&#xD;
at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms).</description>
    <arm_group_label>GS dual sugar permeability test</arm_group_label>
    <arm_group_label>Multi sugar test</arm_group_label>
    <arm_group_label>PEG test</arm_group_label>
    <arm_group_label>Protein test</arm_group_label>
    <other_name>Indometacin [Actavis]</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy controls, female/male, 18-75 years of age, OR:&#xD;
&#xD;
          -  coeliac disease without taking medicine, female/male, 18-75 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cardiac and/or vascular disease&#xD;
&#xD;
          -  chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  rheumatic arthritis (RA)&#xD;
&#xD;
          -  Inflammatory bowel disease(IBD); Crohn's colitis or colitis ulcerosa&#xD;
&#xD;
          -  Irritable bowel syndrome (IBS)&#xD;
&#xD;
          -  Inflammatory systemic disease&#xD;
&#xD;
          -  Obesity (Body Mass Index ≥ 30 kg/m²)&#xD;
&#xD;
          -  Diabetes Mellitus&#xD;
&#xD;
          -  Thyroid disease&#xD;
&#xD;
          -  Kidney disease&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Substance abuse (alcohol, drug, cocain, opioids, and others)&#xD;
&#xD;
          -  Use of drugs&#xD;
&#xD;
          -  Operations to the GI system, apart from appendectomy&#xD;
&#xD;
          -  Allergy to eggs or milk&#xD;
&#xD;
          -  Hypersensitivity to any of the following: lactulose, l-rhamnose, sucrose, sucralose of&#xD;
             erythritol&#xD;
&#xD;
          -  Acute porphyria or phenylketonuria (PKU)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WA Buurman, Prof.dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Zuid-Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Kim van Wijck</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <keyword>GI</keyword>
  <keyword>gastrointestinal</keyword>
  <keyword>permeability</keyword>
  <keyword>indometacin</keyword>
  <keyword>indomethacin</keyword>
  <keyword>coeliac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

